PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22652896-1 2012 INTRODUCTION: We tested the hypothesis that asymmetric dimethylarginine (ADMA) interferes with other mechanisms in addition to inhibition of nitric oxide synthase (NOS). dimethylarginine 55-71 nitric oxide synthase 2 Homo sapiens 141-162 22313778-1 2012 We produced a monoclonal antibody (mAb) against N(G),N(G)-dimethyl-L-arginine (asymmetric dimethylarginine: ADMA), an endogenous competitive inhibitor of nitric oxide synthase (NOS), and developed an enzyme-linked immunosorbent assay (ELISA). dimethylarginine 90-106 nitric oxide synthase 2 Homo sapiens 154-175 22048724-2 2012 This article concentrates on recent developments on the regulation of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) in CKD and on the importance of the nitric oxide synthases in kidney disease progression, particularly in diabetic nephropathy. dimethylarginine 134-150 nitric oxide synthase 2 Homo sapiens 85-106 21873936-1 2011 BACKGROUND: Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, increases the activity of NF-kappaB (NF-kappaB) and then induces the expression of intercellular adhesion molecule-1 (ICAM-1). dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 62-83 20499035-7 2010 The mechanisms responsible for a decreased NO synthesis are partially known but oxidative stress, overproduction of endogenous inhibitors of the Nitric Oxide Synthase (NOS) such as asymmetric dimethylarginine (ADMA) and genetic factors may be implicated. dimethylarginine 192-208 nitric oxide synthase 2 Homo sapiens 145-166 21490695-1 2011 BACKGROUND: Nitric oxide synthase (NOS) inhibitor asymmetrical dimethylarginine (ADMA) is synthesized by the methylation of arginine as part of the methionine/homocysteine cycle. dimethylarginine 63-79 nitric oxide synthase 2 Homo sapiens 12-33 21406191-1 2011 OBJECTIVES: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) that accumulates in patients with chronic kidney disease (CKD) and predicts cardiovascular outcome. dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 77-98 21377060-1 2011 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 65-86 20421938-1 2010 Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is a predictor of mortality in critical illness. dimethylarginine 13-29 nitric oxide synthase 2 Homo sapiens 65-86 19778944-1 2009 OBJECTIVE: Asymmetrical dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor and cardiovascular risk factor associated with angiogenic disorders. dimethylarginine 24-40 nitric oxide synthase 2 Homo sapiens 53-74 19909255-1 2009 ADMA (asymmetric dimethylarginine) is a cardiovascular risk factor and an endogenous inhibitor of NOS (nitric oxide synthase). dimethylarginine 17-33 nitric oxide synthase 2 Homo sapiens 103-124 19666123-1 2009 UNLABELLED: Infusion of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) causes an elevation of blood pressure and depression of cardiac output. dimethylarginine 88-104 nitric oxide synthase 2 Homo sapiens 39-60 19409491-1 2009 Synthesis of nitric oxide (NO) can be blocked by inhibition of nitric oxide synthase (NOS) active site with guanidino-substituted analogues of l-arginine such as asymmetric dimethylarginine (ADMA). dimethylarginine 173-189 nitric oxide synthase 2 Homo sapiens 63-84 19344390-2 2009 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthases (NOS), is associated with vascular disease in other populations. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-85 19156404-1 2009 OBJECTIVE: Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, can induce the adhesiveness of monocytes to vascular endothelium, and chemokines play an important role in this process. dimethylarginine 22-38 nitric oxide synthase 2 Homo sapiens 61-82 19333216-0 2009 Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase and a novel cardiovascular risk molecule. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-84 19590199-1 2009 BACKGROUND: Asymmetric dimethylarginine (ADMA), the inhibitor of nitric oxide synthase (NOS), has been reported to be associated with glucose metabolism, but its mechanisms remain unknown. dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 65-86 18372578-2 2008 Asymmetrical dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS), can cause endothelial dysfunction by decreasing nitric oxide (NO) and lead to increased risk of thrombosis. dimethylarginine 13-29 nitric oxide synthase 2 Homo sapiens 74-95 18974239-1 2008 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), the enzyme which converts the amino acid arginine into nitric oxide (NO). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 65-86 18204093-3 2008 Pathophysiologic concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), are found in patients with CRD and correlate with vascular disease and cardiovascular mortality. dimethylarginine 46-62 nitric oxide synthase 2 Homo sapiens 98-119 18289604-2 2008 Asymmetric dimethylarginine (ADMA), a major endogenous NO synthase (NOS) inhibitor, could inhibit NO production and induce oxidative stress in endothelial cells. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 55-66 17560156-1 2007 Asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase (NOS), has been identified as a new and emerging contributor to, or marker for, cardiovascular risk. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 52-73 17872491-1 2007 RATIONALE: Asymmetric dimethylarginine (ADMA), a potent endogenous nitric oxide synthase (NOS) inhibitor, is increased in idiopathic pulmonary arterial hypertension and associated with unfavorable outcome. dimethylarginine 22-38 nitric oxide synthase 2 Homo sapiens 67-88 18991678-3 2008 NO is synthesized from L-arginine via the action of NO synthase (NOS), which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA), a naturally occurring amino acid found in plasma and various types of tissues. dimethylarginine 154-170 nitric oxide synthase 2 Homo sapiens 52-63 17512604-1 2007 Elevated cerebrospinal fluid (CSF) concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), are assumed to be related to delayed vasospasm after subarachnoid haemorrhage (SAH). dimethylarginine 64-80 nitric oxide synthase 2 Homo sapiens 116-137 17379959-1 2007 Asymmetric dimethylarginine (ADMA) is an endogenous NO synthase (NOS) inhibitor whose production is enhanced by oxidative stress. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 52-63 17482266-8 2007 The most likely mechanism that explains the occurrence of endothelial dysfunction and the effect of L-arginine is that application of L-arginine antagonizes asymmetric dimethylarginine (ADMA), the endogenous NO synthase (NOS) inhibitor. dimethylarginine 168-184 nitric oxide synthase 2 Homo sapiens 208-219 17479195-2 2007 Asymmetric dimethylarginine (ADMA), a major endogenous NO synthase (NOS) inhibitor, could inhibit NO production in vivo and in vitro. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 55-66 17273169-1 2007 Asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA) are endogenously produced amino acids that inhibit all three isoforms of nitric oxide synthase (NOS). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 141-162 16979918-1 2007 Nitric oxide (NO) synthesis is modulated by dimethylarginine dimethylaminohydrolase (DDAH) via metabolizing asymmetric dimethylarginine (ADMA), an endogenous NO synthase (NOS) inhibitor. dimethylarginine 44-60 nitric oxide synthase 2 Homo sapiens 158-169 16481412-1 2006 Symmetrical dimethylarginine (SDMA) is the structural isomer of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine. dimethylarginine 12-28 nitric oxide synthase 2 Homo sapiens 79-100 17368960-2 2007 NO is synthesized from L-arginine via the action of NO synthase (NOS), which is known to be blocked by endogenous L-arginine analogues such as asymmetric dimethylarginine (ADMA). dimethylarginine 154-170 nitric oxide synthase 2 Homo sapiens 52-63 16516911-1 2006 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is emerging as a key contributor for endothelial dysfunction and its effects on endothelium are not yet completely defined. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-84 16481412-1 2006 Symmetrical dimethylarginine (SDMA) is the structural isomer of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine. dimethylarginine 128-144 nitric oxide synthase 2 Homo sapiens 79-100 16467652-5 2006 Out of these genes, the enzyme relating to the synthesis (PRMT-1) of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), was further examined concomitantly with the degradation enzyme, dimethylarginine dimethylaminohydrolase 2 (DDAH-2). dimethylarginine 80-96 nitric oxide synthase 2 Homo sapiens 132-153 16221223-2 2005 In patients with end-stage renal disease, increased serum concentration of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), has been linked to excess cardiovascular morbidity. dimethylarginine 86-102 nitric oxide synthase 2 Homo sapiens 138-159 16404814-1 2005 An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS),particularly asymmetric dimethylarginine (ADMA), regulate nitric oxide generation in disease states. dimethylarginine 152-168 nitric oxide synthase 2 Homo sapiens 100-121 16024577-2 2005 We hypothesized that coronary endothelial dysfunction in CHF may be due in part to decreased dimethylarginine dimethylaminohydrolase (DDAH), the enzyme that degrades endogenous inhibitors of NO synthase (NOS), including asymmetric dimethylarginine. dimethylarginine 93-109 nitric oxide synthase 2 Homo sapiens 191-202 16148605-0 2005 The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. dimethylarginine 73-90 nitric oxide synthase 2 Homo sapiens 25-46 16148605-1 2005 OBJECTIVES: Impaired nitric oxide generation and accumulation of the endogenous inhibitor of nitric oxide synthase (NOS), asymmetric dimethylarginine (ADMA), have been identified as strong predictors of cardiovascular outcomes in patients with end-stage renal disease (ESRD). dimethylarginine 133-149 nitric oxide synthase 2 Homo sapiens 93-114 15207938-2 2004 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase (NOS). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 77-98 16125868-0 2005 Asymmetric dimethylarginine: a molecule responsible for the coexistence of insulin resistance and atherosclerosis via dual nitric oxide synthase inhibition. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 123-144 16125868-1 2005 Asymmetric dimethylarginine (ADMA) has been recently identified as the major endogenous inhibitor of soluble nitric oxide synthase. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 109-130 15554917-3 2004 The l-arginine analogues asymmetric dimethylarginine (ADMA) and N(G)-monomethyl-l-arginine (l-NMMA) are endogenous inhibitors of nitric oxide synthase (NOS), involved in the physiopathology of arterial hypertension. dimethylarginine 36-52 nitric oxide synthase 2 Homo sapiens 129-150 15827267-1 2005 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) and has been implicated in endothelial dysfunction. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 65-86 15667575-2 2005 In endothelial cells NO is synthesized from the amino acid l-arginine by the action of the NO synthase (NOS), which can be blocked by endogenous inhibitors such as asymmetric dimethylarginine (ADMA). dimethylarginine 175-191 nitric oxide synthase 2 Homo sapiens 91-102 15308550-1 2004 OBJECTIVE: Asymmetrical dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), and its accumulation has been associated with cardiovascular disease. dimethylarginine 24-40 nitric oxide synthase 2 Homo sapiens 78-99 15325021-1 2004 Plasma levels of asymmetric dimethylarginine (ADMA), an endogenously produced competitive inhibitor of nitric oxide synthase (NOS), have been found to be elevated in a large number of disorders characterized by endothelial dysfunction; this remarkable phenomenon has yet to receive a plausible explanation. dimethylarginine 28-44 nitric oxide synthase 2 Homo sapiens 103-124 14662708-0 2004 Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. dimethylarginine 86-102 nitric oxide synthase 2 Homo sapiens 35-56 14662708-1 2004 BACKGROUND: Increased blood concentrations of the endogenous nitric oxide synthase (NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess cardiovascular morbidity and mortality and to progression of renal disease. dimethylarginine 112-128 nitric oxide synthase 2 Homo sapiens 61-82 14664901-1 2003 An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. dimethylarginine 153-169 nitric oxide synthase 2 Homo sapiens 100-121 11950212-1 2002 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), may be related to reduced biosynthesis of nitric oxide in diseases associated with accelerated atherosclerosis. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-84 12625833-3 2003 We have tested the hypothesis that ERT lowers plasma levels of asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of NO synthase (NOS). dimethylarginine 76-92 nitric oxide synthase 2 Homo sapiens 128-139 14633154-1 2003 BACKGROUND: Plasma asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is an independent predictor of overall mortality and cardiovascular outcome in hemodialysis patients. dimethylarginine 30-46 nitric oxide synthase 2 Homo sapiens 82-103 12694305-2 2003 NO is synthesized from the amino acid L-arginine by the action of the NO synthase (NOS), which can be blocked by endogenous inhibitors such as asymmetric dimethylarginine (ADMA). dimethylarginine 154-170 nitric oxide synthase 2 Homo sapiens 70-81 12647267-1 2003 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 65-86 12091378-2 2002 While guanidino-methylated arginines (MA) including asymmetric dimethylarginine (ADMA) and N(G)-methyl-l-arginine (NMA) are potent competitive inhibitors of nitric oxide synthase (NOS) and are released upon protein degradation, it is unknown whether their intracellular concentrations are sufficient to critically regulate neuronal NO production and secondary cellular function or injury. dimethylarginine 63-79 nitric oxide synthase 2 Homo sapiens 157-178 8743168-0 1995 Effect of asymmetric dimethyl arginine on nitric oxide synthase activity in normal and pre-eclamptic placentae. dimethylarginine 21-38 nitric oxide synthase 2 Homo sapiens 42-63 10802528-2 2000 The activity of NO synthase (NOS) may be regulated by endogenous NOS inhibitors such as asymmetric dimethylarginine (ADMA). dimethylarginine 99-115 nitric oxide synthase 2 Homo sapiens 16-27 10377069-1 1999 BACKGROUND: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 77-98 8743168-1 1995 An endogenous inhibitor of nitric oxide synthase (NOS), NG,NG dimethylarginine (asymmetric dimethylarginine, ADMA), which is present in human plasma and urine, has been reported to be elevated in the plasma of women with pre-eclampsia. dimethylarginine 62-78 nitric oxide synthase 2 Homo sapiens 27-48 8743168-1 1995 An endogenous inhibitor of nitric oxide synthase (NOS), NG,NG dimethylarginine (asymmetric dimethylarginine, ADMA), which is present in human plasma and urine, has been reported to be elevated in the plasma of women with pre-eclampsia. dimethylarginine 91-107 nitric oxide synthase 2 Homo sapiens 27-48 34604419-1 2021 Background: Asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase (NOS), has been implicated in endothelial dysfunction and atherogenesis. dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 64-85 18295546-1 2008 Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, has been implicated in vascular inflammation through induction of reactive oxygen species (ROS) and proinflammatory genes in endothelial cells. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 50-71 31993367-3 2019 The dimethylarginine dimethylaminohydrolase (DDAH) family of enzymes metabolize the endogenous nitric oxide synthase (NOS) inhibitors, asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA), and are thus key for maintaining homeostatic control of NO. dimethylarginine 4-20 nitric oxide synthase 2 Homo sapiens 95-116 33646184-1 2021 BACKGROUND: Asymmetric Dimethyl Arginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS) is important in different diseases characterized by decreased nitric oxide (NO) availability. dimethylarginine 23-40 nitric oxide synthase 2 Homo sapiens 78-99 33195431-5 2020 Results: The analysis of plasma AA metabolite patterns revealed the number of changes including an increase (20%) in concentrations of NO synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) in SSc vs. healthy subjects. dimethylarginine 174-190 nitric oxide synthase 2 Homo sapiens 135-146 33271854-2 2020 Asymmetric dimethylarginine (ADMA) inhibits nitric oxide synthase (NOS) and is associated with DCI after SAH. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 44-65 31993367-3 2019 The dimethylarginine dimethylaminohydrolase (DDAH) family of enzymes metabolize the endogenous nitric oxide synthase (NOS) inhibitors, asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA), and are thus key for maintaining homeostatic control of NO. dimethylarginine 146-162 nitric oxide synthase 2 Homo sapiens 95-116 31763675-3 2019 Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor that is largely metabolised by dimethylarginine dimethylaminohydroxylase (DDAH) in humans. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 52-73 31714895-2 2019 In cultured airway epithelial cells, L-citrulline, a precursor of L-arginine recycling and NO formation, has been shown to prevent asymmetric dimethyl arginine-mediated (ADMA-mediated) NO synthase (NOS2) uncoupling, restoring NO and reducing oxidative stress.METHODSIn a proof-of-concept, open-label pilot study in which participants were analyzed before and after treatment, we hypothesized that 15 g/d L-citrulline for 2 weeks would (a) increase the fractional excretion of NO (FeNO), (b) improve asthma control, and (c) improve lung function. dimethylarginine 142-159 nitric oxide synthase 2 Homo sapiens 198-202 30932011-1 2019 Raised circulating concentrations of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), have been reported in several rheumatic diseases (RDs). dimethylarginine 48-64 nitric oxide synthase 2 Homo sapiens 100-121 31337005-3 2019 NO synthases (NOS) use l-arginine (Arg) as a substrate, as asymmetric dimethylarginine (ADMA) is a direct endogenous inhibitor of NOS. dimethylarginine 70-86 nitric oxide synthase 2 Homo sapiens 0-12 30611984-1 2019 Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is a key enzyme involved in the metabolism of the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethylarginine (ADMA) and monomethyl arginine (L-NMMA). dimethylarginine 161-177 nitric oxide synthase 2 Homo sapiens 111-132 29150732-2 2018 DDAH1 regulates nitric oxide (NO) production by degrading endogenous nitric oxide synthase (NOS) inhibitor, asymmetric dimethylarginine (ADMA). dimethylarginine 119-135 nitric oxide synthase 2 Homo sapiens 69-90 30071927-3 2018 The present study investigates the predictive role of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) and its stereoisomer symmetric dimethylarginine (SDMA) for cardiovascular risk, all-cause mortality, and renal function in patients with anti-neutrophil-cytoplasmic antibodies-associated small vessel vasculitis (AASV) subjected to standardized treatment regimens in four European Vasculitis Study Group trials representing all stages of renal disease. dimethylarginine 118-134 nitric oxide synthase 2 Homo sapiens 69-90 29070803-1 2017 Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is responsible for metabolism of an endogenous inhibitor of nitric oxide synthase (NOS), asymmetric dimethylarginine (ADMA), which plays a key role in modulating angiogenesis. dimethylarginine 150-166 nitric oxide synthase 2 Homo sapiens 110-131 27216780-1 2018 INTRODUCTION: Asymmetric dimethylarginine (ADMA) competitively inhibits nitric oxide synthase (NOS). dimethylarginine 25-41 nitric oxide synthase 2 Homo sapiens 72-93 29128547-6 2018 METHODS: In the plasma and urine of 10 hypogonadal men, we measured the major NO metabolites nitrite and nitrate and the endogenous inhibitor of NO synthase (NOS), i.e., asymmetric dimethylarginine (ADMA), before and after a 24-week testosterone treatment to normalize plasma testosterone levels. dimethylarginine 181-197 nitric oxide synthase 2 Homo sapiens 145-156 28580735-4 2017 Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is the main enzyme that can degrade asymmetric dimethylarginine, an endogenous nitric oxide synthase (NOS) inhibitor. dimethylarginine 97-113 nitric oxide synthase 2 Homo sapiens 129-150 26790728-2 2016 Asymmetric dimethylarginine (ADMA), the main endogenous inhibitor of nitric oxide synthase (NOS), plays a critical role in the process of atherosclerosis in a uremic environment. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 69-90 28153724-3 2017 Despite their utility, all NSAIDs are associated with increased risk of cardiovascular side effects which our recent work suggests could be mediated by increased levels of the endogenous NO synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) leading to reduced endothelial NOS activity and associated endothelial cell dysfunction. dimethylarginine 226-242 nitric oxide synthase 2 Homo sapiens 187-198 28294182-1 2017 Asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), impairs the beneficial effect of NO. dimethylarginine 13-29 nitric oxide synthase 2 Homo sapiens 65-86 26996393-1 2016 BACKGROUND: Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that can degrade asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor. dimethylarginine 103-119 nitric oxide synthase 2 Homo sapiens 142-163 27479314-1 2016 BACKGROUND: Elevated plasma concentrations of the endogenous nitric oxide synthase (NOS) inhibitor asymmetric dimethylarginine (ADMA) have been observed in respiratory conditions such as asthma and cystic fibrosis. dimethylarginine 110-126 nitric oxide synthase 2 Homo sapiens 61-82 27175806-2 2016 Asymmetric dimethylarginine (ADMA), which is an endogenous inhibitor of nitric oxide synthase (NOS), has been demonstrated to be involved in the pathophysiological processes of endothelial dysfunction and salt-sensitive hypertension. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 72-93 27083312-2 2016 Asymmetrical dimethylarginine (ADMA), formed by the hydrolysis of proteins containing methylated arginine residues, is an endogenous inhibitor of nitric oxide synthase (NOS), which oxidize l-arginine to citruline and nitric oxide (NO), related to hyperinsulinaemia and hyperlipidaemia. dimethylarginine 13-29 nitric oxide synthase 2 Homo sapiens 146-167 27105159-10 2016 Moreover, nitric oxide (NO) bioavailability and its relation with the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethylarginine (ADMA) and l-NG-monomethylarginine (l-NMMA), renin release by juxtaglomerular cells and aldosterone pathway, seem to determine NSAID safety also. dimethylarginine 131-147 nitric oxide synthase 2 Homo sapiens 81-102 26985445-3 2016 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of NO synthase (NOS), contributes to endothelial dysfunction and is associated with mortality in adults with falciparum malaria. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-74 24895913-1 2014 The NOS (nitric oxide synthase) inhibitor ADMA (asymmetric dimethylarginine) contributes to the pathogenesis of pulmonary hypertension. dimethylarginine 59-75 nitric oxide synthase 2 Homo sapiens 9-30 26407009-2 2015 Dimethylarginine dimethylaminohydrolase (DDAH) regulates endothelial NO synthesis by maintaining homeostasis between asymmetric dimethylarginine (ADMA), an endogenous NO synthase (NOS) inhibitor, and arginine, the NOS substrate. dimethylarginine 128-144 nitric oxide synthase 2 Homo sapiens 167-178 25793525-1 2015 OBJECTIVE: We determined, for packed red blood cells (PRBC) and fresh frozen plasma, the maximum content, and ability to release the endogenous nitric oxide synthase (NOS) inhibitors asymmetric dimethylarginine (ADMA) and monomethylarginine (LNMMA). dimethylarginine 194-210 nitric oxide synthase 2 Homo sapiens 144-165 25576847-1 2015 BACKGROUND: Asymmetric dimethylarginine (ADMA), which acts an endogenous inhibitor of nitric oxide synthase (NOS), is involved in the pathogenesis of cardiovascular disease. dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 86-107 25209804-1 2015 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), is emerging as a key contributing factor in atherogenesis, a process in turn known to involve macrophage apoptosis. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 63-84 26420019-1 2015 Dimethylarginine dimethylaminohydrolase (DDAH) is a key enzyme involved in the metabolism of asymmetric dimethylarginine (ADMA) and N-monomethyl arginine (NMMA), which are endogenous inhibitors of the nitric oxide synthase (NOS) family of enzymes. dimethylarginine 104-120 nitric oxide synthase 2 Homo sapiens 201-222 25095755-2 2014 Asymmetric dimethylarginine (ADMA) reduces the level of NO by inhibiting nitric oxide synthase (NOS) enzyme. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 73-94 22353385-1 2013 BACKGROUND: Epidemiologic investigations have linked the circulating levels of asymmetric dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide synthase (NOS), to carotid intima-media thickness (IMT). dimethylarginine 90-106 nitric oxide synthase 2 Homo sapiens 142-163 24992596-4 2014 Asymmetric dimethylarginine (ADMA) can inhibit nitric oxide synthase (NOS) and regulate local NO/ROS balance. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 47-68 24739810-1 2014 Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor known as a mediator of endothelial dysfunction and atherosclerosis. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 52-73 24834905-1 2014 AIM: Asymmetric dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor that decreases NO production and promotes the development of cardiovascular diseases. dimethylarginine 16-32 nitric oxide synthase 2 Homo sapiens 45-66 24727752-1 2014 BACKGROUND: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelium nitric oxide synthase (NOS). dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 89-110 23702602-1 2013 Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS), which can be hydrolyzed by dimethylarginine-dimethylaminohydrolase (DDAH). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 65-86 23129820-1 2013 BACKGROUND: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthase (NOS). dimethylarginine 23-39 nitric oxide synthase 2 Homo sapiens 77-98 22779953-3 2012 Asymmetric dimethylarginine (ADMA), an endogenous inhibitor of endothelial nitric oxide synthase (NOS) has been linked to endothelial dysfunction. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 75-96 23443106-1 2012 Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, is known as mediator of endothelial cell dysfunction and atherosclerosis. dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 50-71 23175152-1 2013 Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase (NOS) inhibitor, accumulates in plasma during chronic kidney disease (CKD). dimethylarginine 11-27 nitric oxide synthase 2 Homo sapiens 50-71 23710196-4 2013 Newer evidence suggests that a potential explanation for this paradoxical relationship is related to nitric oxide synthase (NOS) uncoupling, which occurs due to an imbalance between L-arginine (NOS substrate) and its endogenous inhibitor, asymmetric di-methyl arginine (ADMA). dimethylarginine 250-268 nitric oxide synthase 2 Homo sapiens 101-122 23379703-1 2012 INTRODUCTION: Each year, 40 million tourists worldwide are at risk of getting acute mountain sickness (AMS), because they travel to altitudes of over 2500 m. As asymmetric dimethylarginine (ADMA) is a nitric oxide synthase (NOS) inhibitor, it should increase pulmonary artery pressure (PAP) and raise the risk of acute mountain sickness and high-altitude pulmonary edema (HAPE). dimethylarginine 172-188 nitric oxide synthase 2 Homo sapiens 201-222 22460174-2 2012 The nitric oxide synthase (NOS)/dimethylarginine dimethylaminohydrolase (DDAH)/asymmetric dimethylarginine (ADMA) pathway is central to this regulation. dimethylarginine 32-48 nitric oxide synthase 2 Homo sapiens 4-25